Index/Topics/Ribociclib for HR+/HER2- Metastatic Breast Cancer

Ribociclib for HR+/HER2- Metastatic Breast Cancer

The use of Ribociclib (Kisqali) in combination with an aromatase inhibitor for the treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer, including its efficacy, safety, and cost-effectiveness.